Pathologie Parameters and
Flow Cytometric Ploidy
Analysis in Predicting
Recurrence in Carcinoma
of the Prostate

Voges, G.; Eigner, Edward B.; Ross, William; Sussman, H.; Stöckle, Michael; Freiha, Fuad S.; Stamey, T A

doi:10.1159/000474280

Cited by 9 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DNA ploidy of prostate carcinoma is a generally accepted prognostic marker for outcome 1–11. However, this information is based on assessing DNA content by flow cytometry in paraffin‐embedded tissue sections from RRP specimens.…”

Section: Discussionmentioning

confidence: 99%

“…DNA ploidy analysis of prostate carcinoma generally is viewed as an indicator of biologic behavior independent of standard markers such as Gleason score and pathologic stage 1–11. However, data regarding the utility of ploidy analysis originally were based on assessment of tissue blocks from radical retropubic prostatectomy (RRP) specimens evaluated by flow cytometry 2, 7–11.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen

Sebo

Cheville

Riehle

et al. 2001

Cancer

View full text Add to dashboard Cite

BACKGROUND DNA ploidy analysis of prostate carcinoma is a generally accepted prognostic marker, particularly when tumors are extraprostatic at the time of surgery. In the past decade, the DNA content of prostate carcinoma frequently has been assessed in needle biopsy specimens based on the assumption that ploidy, in conjunction with serum prostate specific antigen (PSA) and Gleason score, provides valuable pretreatment information. METHODS Between 1995 and 1998, the authors identified a consecutive series of 454 prostate carcinomas, verified by needle biopsies and followed by radical retropubic prostatectomies (RRP). Based on the needle biopsies, DNA ploidy and MIB‐I immunostaining were measured by digital image analysis (DIA). The authors also quantified the percent of nuclei in four categories from the DNA histograms. The DIA data were combined with the age of the patient at diagnosis, the serum PSA, Gleason score, percent cores and percent surface area positive for carcinoma, and status of perineural invasion in multivariate models using tumor volume and risk of extraprostatic extension (EPE) at RRP as the outcome variables. RESULTS Joint predictors of tumor volume at RRP were the percent cores positive for carcinoma (P < 0.0001), serum PSA (P < 0.0001), the percent surface area positive for carcinoma (P < 0.0001), and the percent nuclei classified by DNA quantification to be in the “S‐phase” category (P = 0.03). Joint predictors of risk of EPE were the percent cores positive for carcinoma (P = 0.0004), a Gleason score of 7 (P < 0.0001), a Gleason score of 8 or 9 (P < 0.0001), serum PSA (P = 0.006) and perineural invasion (P = 0.02). CONCLUSIONS After adjusting for traditional prognostic markers, DNA ploidy interpretation and MIB‐I quantitation of prostate carcinoma did not appear to jointly predict either outcome variable in the multivariate models. However, a quantitative measure related to both ploidy and proliferation, the percent of nuclei in the putative “S‐phase” category from the DIA histograms, was found to jointly predict for tumor volume. Cancer 2001;91:02196–204. © 2001 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen

Sebo

Cheville

Riehle

et al. 2001

Cancer

View full text Add to dashboard Cite

show abstract

“…Studies evaluating DNA ploidy in prostate cancer have come to varying conclusions. Some studies on 45-850 (mean 139) cancers have suggested a relevant prognostic impact of ploidy (7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20), while other studies on 33-447 (mean 122) cancers have failed to find significant associations (7,(20)(21)(22)(23)(24). Deletions affecting various chromosomal loci are a hallmark of prostate cancer.…”

Section: Introductionmentioning

confidence: 99%

The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate Cancer

Lennartz

Minner

Brasch

et al. 2016

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…[193] found the same after external radiation in a multivariate analysis. 4 level 3b studies [187][188][189][190] proved a significant correlation of DNA-ploidy parameters with recurrence free survival time after radical prostatectomy on multivariate analyses ( Table 4). …”

Section: Methodologically Sufficient Papersmentioning

confidence: 96%

DNA-cytometric grading of prostate cancer Systematic review with descriptive data analysis

Böcking¹,

Tils²,

Schramm³

et al. 2014

Pathol Discov

View full text Add to dashboard Cite

Gleason-score <=6, assessed on core needle biopsies, is an essential prognostic parameter to offer the strategy of Active Surveillance (AS) to patients with locally confined cancers of the prostate. Yet, its interobserver reproducibility is low (48-70%) and its prognostic validity unsatisfactory. An option to complementary assess the malignant potential of these cancers are objective DNA-ploidy-measurements on existing biopsies. For that purpose chromosomal heterogeneity is indirectly quantified by DNA-cytometry resulting in DNA-grades of malignancy 1-4. This review systematically trawls and evaluates all scientific publications on the potential diagnostic and prognostic validity and the heterogeneity of DNA-ploidy measurements in cancers of the prostate between 1966 and 2013. Publications have been classified into Oxford levels of evidence and levels of significance were given for the correlation of DNA-ploidy with different clinical outcomes. 114 scientific articles had to be excluded because of different methodological reasons. All but one of the 67 methodologically acceptable articles report on a significant diagnostic resp. prognostic significance of DNA ploidy measurements in cancers of the prostate. 8 level 1b studies report that DNA-ploidy, assessed on punch biopsies independently predicts organ confinement as assessed after radical prostatectomy. 18 level 2b studies prove that DNA-ploidy measurements add statistically significant information to the Gleason-score. 16 level 2b investigations report a significant correlation of DNA-ploidy with recurrence-free survival. 15 level 2b studies document a significant correlation with overall survival after different types of therapy. 5 level 2b investigations prove a significant correlation with local recurrence or progress after radical prostatectomy. 3 level 2b publications show a significant correlation of DNAploidy with the occurrence of lymph node-or bone metastases after radical prostatectomy. 1 level 2b study documents the additional prognostic value of DNA-ploidy measurements over conventional subjective grading in prostate cancer patients under AS. All existing 15 narrative reviews on selected articles dealing with prognostic DNA-cytometry in cancers of the prostate are in favor of this method. Prospective level 1b studies, especially those proving the validity of DNA ploidy measurements to predict non-progression in patients with clinically insignificant low-grade low stage cancers of the prostate eligible for Active Surveillance additionally to the Gleason-score are still missing.

show abstract

Pathologie Parameters and Flow Cytometric Ploidy Analysis in Predicting Recurrence in Carcinoma of the Prostate

Cited by 9 publications

References 18 publications

Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen

Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen

The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate Cancer

DNA-cytometric grading of prostate cancer Systematic review with descriptive data analysis

Contact Info

Product

Resources

About